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The let-23 gene encodes a Caenorhabditis elegans homolog of the epidermal growth factor receptor (EGFR)
necessary for vulval development. We have characterized a mutation of let-23 that activates the receptor and
downstream signal transduction, leading to excess vulval differentiation. This mutation alters a conserved
cysteine residue in the extracellular domain and is the first such point mutation in the EGFR subfamily of
tyrosine kinases. Mutation of a different cysteine in the same subdomain causes a strong loss-of-function
phenotype, suggesting that cysteines in this region are important for function and nonequivalent. Vulval
precursor cells can generate either of two subsets of vulval cells (distinct fates) in response to sa62 activity. The
fates produced depended on the copy number of the mutation, suggesting that quantitative differences in
receptor activity influence the decision between these two fates.
Cells differentiate in response to a variety of extracellular
signals; receptor tyrosine kinases (RTKs) receive some of these
signals and transduce the information to other components
within the cell. Signal transduction pathways involving RTKs
are conserved in mammals, insects, and nematodes (reviewed
in references 16 and 56). RTKs normally are activated by
ligand binding, followed by receptor dimerization and covalent
modification of the receptor by autophosphorylation on ty-
rosine. This activation transduces the signal into the cytoplasm
(16, 56, 71). Mutations may cause inappropriate RTK activity
by interfering with regulation or by conferring hypersensitivity
to ligand or ligand-independent activity via a change in con-
formation. Because many RTK pathways control cell prolifer-
ation, such mutations can be oncogenic (42, 71, 78).
The let-23 gene of the nematode Caenorhabditis elegans en-
codes a member of the epidermal growth factor (EGF) recep-
tor (EGFR) family (1) (Fig. 1A). let-23 is required for larval
viability, vulval differentiation, formation of male mating struc-
tures, fertility, and specification of the P11 and P12 neurecto-
blasts (3, 17, 23). Complete loss of let-23 function causes death
in the first stage of larval development. Reduction-of-function
mutations in let-23 are pleiotropic; some alleles cause only a
subset of defects. For example, the allele let-23(sy10) causes
partial reduction of survival, vulval differentiation, male spi-
cule differentiation, and complete loss of fertility (3). LET-23
acts in a genetically defined signal transduction pathway that
parallels the biochemically defined EGFR pathway of mam-
malian cells (reviewed in reference 63). Downstream effectors
include SEM-5, a GRB2 homolog that has SH2 and SH3 do-
mains (10, 61), LET-60 and LIN-45, homologs of ras and raf,
respectively (20, 21), a Mek homolog (39, 77), and a mitogen-
activated protein kinase homolog (43, 76).
LET-23 is essential for vulval differentiation. The vulva of C.
elegans is made from the progeny of three of six multipotent
vulval precursor cells (VPCs). In response to the LIN-3 induc-
tive signal, produced by the anchor cell in the adjacent gonad
(24), these three cells adopt vulval fates and differentiate to
form vulval tissue. The vulval fates are of two types, designated
18 and 28. The other three VPCs normally adopt a nonvulval
epidermal fate, designated 38 (reviewed in reference 30).
Reduction-of-function mutations in let-23 or other genes in
the pathway cause fewer than three VPCs to adopt vulval fates.
In extreme cases, all six VPCs adopt epidermal fates and no
vulva is made. This phenotype is called vulvaless (Vul) (re-
viewed in reference 63). Excess pathway activity, due to lin-3
overexpression or let-60 ras gain-of-function mutations, causes
more than three VPCs to adopt vulval fates. This leads to
formation of ectopic pseudovulvae, a phenotype called multi-
vulva (Muv) (6, 19, 34).
We have characterized sa62, the first known activating mu-
tation of let-23. This mutation causes a semidominant pheno-
type, excess differentiation of the VPCs, that occurs even in the
absence of inductive signal from the gonad. The ligand-inde-
pendent activity can induce either the 28 or 18 vulval fate,
depending on the copy number of the mutant gene. We com-
pared the gain-of-function phenotypes to loss-of-function phe-
notypes caused by a similar codon change in the same domain
and tested the effects of analogous mutations in the human
EGFR.
MATERIALS AND METHODS
General methods. Methods for culturing, handling, and genetic manipulation
of C. elegans were performed as described previously (8). Unless otherwise
noted, strains were maintained at 208C. We use the standard C. elegans cellular
and genetic nomenclature (29, 66). Mutations used are as described in reference
8 or as noted. The following mutations were used: LG I, dpy-5(e61), lin-10(e1439)
(17), unc-13(e51); LG II, let-23(mn23), (sy16), (sy17), (sy1) (3, 23), dpy10(e128),
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unc-4(e120), rol-6(e187), unc-52(e444), rol-1(e91), mnC1[dpy-10(e128) unc-
52(e444)] (23), lin-7(e1413) (17, 31); LG III, unc-32(e189); LG IV, dpy-20(e1282)
(25, 66), lin-3(n378), (n1059) (17), unc-22(e66), unc-24(e138), let-60(sy100) (19),
nT1[unc(n754dm) let] (IV; V) (17), nT1[let(m435)] (52); LG V, dpy-11(e224),
him-5(e1490) (26); and LG X, lon-2(e678), sem-5(n2019) (10), lin-2(e1309) (17,
28).
Genetic analysis. (i) Backcrossing. sa62, isolated from a screen of ethyl meth-
anesulfonate-mutagenized animals, was generously provided by J. H. Thomas.
We backcrossed the sa62 strain twice, first to a lon-2(e678) strain and then to the
wild-type strain N2. In the course of the second backcross, we isolated a line of
animals that had lost a linked recessive lethal mutation, which we designated
sy220.
Further backcrossing revealed the presence of an interacting mutation which
we designated sy322. This unlinked mutation increased the penetrance of the
sa62Muv phenotype. In sa62 e120; sy322 homozygotes, 4 to 6 (an average of 5.3)
VPCs adopted vulval fates (100% of animals were Muv, n 5 54) at 208C. In
comparison, in sa62 e120 homozygotes, 3 to 5.5 (an average of 4.2) VPCs
adopted vulval fates (90% were Muv) at 208C (Table 1). In sa62 e120/mnC1;
sy322 animals, 3 to 5 (an average of 3.6) VPCs adopted vulval fates (70% of
animals were Muv, n 5 93), while in sa62 e120/mnC1 animals, 3 to 4 (an average
of 3.04) VPCs adopted vulval fates (6% were Muv). sy322 does not suppress the
Vul phenotype of let-23(sy1) or let-23(sy97) (data not shown).
(ii) Mapping to chromosome II. We mated let-23(sa62)/1; lon-2 or let-23
(sa62) let(sy220)/11; lon-2 animals with males heterozygous for one of the
chromosomal markers. From Muv (sa62/1; marker/1 or sa621/11; marker/1)
non-Lon F1 progeny from each cross, we isolated F2 progeny that were homozy-
gous for the marker. F3 progeny were scored for presence of the Muv phenotype
(and the sy220 Let phenotype if applicable). If the marker is linked to sa62 and
sy220, most animals homozygous for the marker should give no Muv or Let
progeny. If the marker is unlinked, two-thirds of animals homozygous for the
marker should produce Muv and Let progeny. let-23(sa62) and let(sy220) showed
linkage to dpy-10 and assorted independently from dpy-5, unc-32, dpy-20, dpy-11,
and lon-2.
Three-factor mapping located let(sy220) close to or to the right of rol-1 [15 of
16 Dpy non-Let recombinants from rol-1(e91)/dpy-10(e128) sy220 animals pro-
duced Rol progeny].
(iii) Three-factor mapping of sa62. To balance the right arm of chromosome
II, we used mnC1[dpy-10(e128) unc-52(e444)] (23). sa62/mnC1; him-5(e1490)
males were mated to let-23(mn23) unc-4(e120)/mnC1 or rol-6(e187) let-23(sy16)/
mnC1 hermaphrodites. Both mn23 and sy16 are lethal alleles of let-23 (3, 23).
Progeny of the let-23(sa62)/let-23(mn23) unc-4 or let-23(sa62)/rol-6 let-23(sy16)
heterozygotes were screened for viable Unc or Rol progeny. These recombinants
were isolated, and their progeny were examined for the presence of Muv animals.
All 36 Unc non-Let animals and all 24 Rol non-Let animals produced Muvs,
indicating that they carried sa62. These values placed sa62 within 0.1 map unit of
let-23 with 95% confidence.
(iv) Mutagenesis and cis-trans test. Since animals carrying sa62 in trans to
lethal let-23 alleles were healthy with a partially penetrant Muv phenotype (Table
2), if sa62 were caused by a mutation in a linked but different gene, it should also
produce the Muv phenotype in cis to a let-23 loss-of-function (lethal) allele. In
contrast, if sa62 were a let-23 mutation, we would expect a lethal allele of let-23
to be a cis-dominant suppressor of the sa62 Muv phenotype.
We isolated lethal alleles of let-23 in cis to sa62 by mutagenesis. Animals were
mutagenized with ethyl methanesulfonate (8), and 10 to 20 mutagenized let-23
(sa62) unc-4(e120) hermaphrodites per plate were mated with eight let-23(sy1);
him-5(e1490) males. let-23(lethal)/let-23(sy1) animals are viable but defective in
egg laying (Egl phenotype) because they are Vul (3). We picked Egl F1 progeny
from independent plates and isolated descendants homozygous for him-5.
From 4,800 F1 progeny we isolated three Egl mutants that produced dead
larvae of the let-23(lethal) type. The three alleles were designated sy264, sy265,
and sy266. We outcrossed two of these (sy264 and sy265) and showed that they
failed to complement the lethality of let-23(sy16) and the Egl defect of sy1. The
third isolate (sy266) could not be outcrossed, as males had severely crumpled
spicules, and hermaphrodites were Vul.
We constructed let-23(sa62 sy264) unc-4/mnC1 and let-23(sa62 sy265) unc-4/
mnC1 strains and examined them with Nomarski optics to score vulval differen-
FIG. 1. Comparison of LET-23 and EGFR. (A) Schematic representations of
LET-23 and EGFR structures. Asterisks mark approximate locations of mutated
cysteines. (B) Sequence comparison of EGFR family members. The numbers
flanking each sequence indicate the positions of the first and last amino acids
shown (1, 11, 44, 49, 50, 70, 72).
TABLE 1. Vulval differentiation in let-23(sa62) animals





sa62/1c 3.04 6 162
sa62/sa62d 4.2 89 147
a sa62 is linked to unc-4(e120) as a marker, and let-23(1) is on the mnC1
balancer chromosome.
b Average number of VPCs per animal that differentiated to vulval fates. The
wild-type value is 3.00.
c sa62e120/mnC1 heterozygote descended from sa62 e120/mnC1 heterozygotes
or from mated sa62 e120/sa62 e120 homozygotes.
d sa62 e120 homozygotes descended from sa62 e120/mnC1 heterozygotes or
from sa62 e120/sa62 e120 homozygotes.
TABLE 2. Vulval differentiation in transgenic animals
Genotype (chromo-
some, transgene)a % Muv
No. of animals
examined
mn23/1, Tyr-359 28b 157
mn23/mn23, Tyr-359 31b 155
mn23/1, Cys-359 #0.1c .500
mn23/mn23, Cys-359 #0.1c .500
a The lethal allele let-23(mn23) is linked to unc-4(e120) as a marker and placed
in trans to mnC1 in heterozygotes. Transgenic strains also carry the unlinked
marker dpy-20(e1282). The transgene is present on an extrachromosomal array
consisting of pk7s62 (Tyr-359) or pk7-13.8 (Cys-359) together with pMH86 (a
plasmid that rescues the Dpy-20 defect) as a marker.
b Data from three stable lines.
c Data from 10 stable lines.
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tiation and P11/P12 fate. All 109 sa62 sy264/11 and 51 sa62 sy265/11 animals
examined were wild type. Therefore, sy264 and sy265 are dominant suppressors
of the Muv phenotype when in cis to sa62. For analysis of the trans phenotype,
we used rol-6(e187) let-23(sy17)/sa62 unc-4(e120). sy17 mutates the 59 splice
donor of intron 4 and causes a larval lethal phenotype; thus, it is likely to cause
complete loss of LET-23 function (2). Of these 60 trans heterozygotes, 7 were
Muv. Since sy264 and sy265 are cis-dominant suppressors of sa62, we concluded
that sa62 is a let-23 allele.
(v) Epistasis tests. We performed epistasis tests with alleles of lin-3, sem-5,
let-60, lin-2, lin-7, and lin-10. We constructed double-mutant strains heterozygous
for sa62 and one of the Vul mutations and examined the vulval phenotypes of
their progeny. If sa62 is epistatic to the Vul mutation, then Muv progeny will
produce only Muv progeny, but Vul progeny may segregate Vul (genotype sa62
/1; vul) or Muv (genotype sa62; vul) progeny. If the Vul mutation is epistatic to
sa62, then Muv progeny may segregate Muv (genotype sa62; vul/1) or Vul
(genotype sa62; vul) progeny, while Vul progeny will produce only Vul progeny.
When homozygous double mutants were identified, we quantitated vulval dif-
ferentiation by examination with Nomarski optics. In wild-type animals, exactly
three of the six VPCs adopt vulval fates. Vulval differentiation of more than 3.0
VPCs indicates a Muv phenotype; vulval differentiation of fewer than 3.0 VPCs
indicates a Vul phenotype.
For tests with let-23(sa62) and lin-3, we used two lin-3 alleles: a genetically null
allele, n1059, and an allele which retains some activity, n378 (17). n1059/n378 is
the lin-3 genotype that has the most severe Vul phenotype and yet is viable.
let-23(sa62) unc-4(e120)/mnC1 males were mated to lin-3(n378) unc-22(e66)
hermaphrodites. L4 (fourth larval stage) males from the cross were mated to
unc-24(e138) lin-3(n1059) dpy-20(e1282)/DnT1 hermaphrodites. As DnT1 dom-
inantly confers paralysis, nonparalyzed cross progeny carry lin-3(n1059) rather
than DnT1. A strain of genotype sa62 unc-4/1; 1 lin-3(n378) unc-22 1/unc-24
lin-3(n1059) 1 dpy-20 was isolated from these cross progeny.
For tests with let-23(sa62) and sem-5(n2019), let-23(sa62) unc-4(e120)/mnC1
males were mated to sem-5(n2019) hermaphrodites (10), and F1 hermaphrodites
of genotype sa62 unc-4/11; sem-5/1 were isolated.
For tests with let-23(sa62) and let-60(sy100dn), we used let(m435)nT1[unc
(n754dm let)], referred to as let nT1, to balance the lin-3 region. let-23(sa62)
unc-4(e120)/mnC1 males were mated to let nT1/let-60(sy100dn) dpy-20(e1282)
hermaphrodites. As let nT1 confers embryonic lethality and let-60(sy100dn) is a
recessive larval lethal mutation (19), F1 hermaphrodites that segregated dead
larvae but no dead embryos and no mnC1 progeny had the desired genotype
[sa62 unc-4/11; let-60(sy100dn) dpy-20/11].
For tests with let-23(sa62) and lin-2(e1309), let-23(sa62)/mnC1; him-5(e1490)
males were mated to rol-6(e187); lin-2(e1309) hermaphrodites (17, 31), and F1
progeny of genotype sa62/rol-6; lin-2/1 were isolated.
For tests with let-23(sa62) and lin-7(e1413), let-23(sa62)/mnC1; him-5(e1490)
males were mated to unc-4(e120) lin-7(e1413) (17, 31) hermaphrodites. From
sa62/unc-4 lin-7 progeny, we isolated Vul non-Unc recombinants (genotype sa62
1 lin-7/ 1 unc-4 lin-7). To confirm the wild-type genotype, N2 [let-23(sa62)]
males were mated to unc-4(e120) lin-7(e1413) hermaphrodites. Their male prog-
eny (genotype unc-4 lin-7/1) were mated to putative let-23(sa62) lin-7 (Muv)
homozygotes. Vul animals [genotype 1 unc-4 lin-7/let-23(sa62) 1 lin-7] were
isolated. Their progeny segregated both Muv and Vul progeny, confirming that
both let-23(sa62) and lin-7(e1413) were present.
For tests with let-23(sa62) and lin-10(e1439), let-23(sa62)/mnC1; him-5(e1490)
males were mated to unc-13(e51) lin-10(e1439) hermaphrodites (17). To confirm
the genotype of the double homozygote, putative let-23(sa62) unc-13 lin-10
hermaphrodites were mated to N2 males. Their progeny segregated Muvs and
Vuls, confirming that let-23(sa62) and lin-10 were present.
Molecular analysis. Unless otherwise noted, subcloning and DNA manipula-
tions were performed according to standard methods (4, 54).
(i) Sequence analysis. Eight sets of primers that span the entire coding se-
quence and the intron-exon boundaries of let-23 (;8.5 kb) were designed (1, 2).
By using these primers, DNA from nematodes homozygous for let-23(sa62) and
from wild-type nematodes were amplified by PCR under the following condi-
tions: 948C for 3 min, then 30 cycles of 948C for 1 min, 558C for 0.5 min, and 728C
for 1.5 min, followed by 728C for 7 min. Each amplified fragment was gel purified
by using Geneclean II (Bio 101 Inc., La Jolla, Calif.) and sequenced by the
dideoxy double-strand method, using a Sequenase kit (U.S. Biochemical, Cleve-
land, Ohio) (40). The mutation was sequenced twice, using DNA from two
independent animals.
(ii) Molecular reconstruction of the Cys-3593Tyr (C359Y) mutation in let-23.
pk7-13.8 is a 15-kb subclone that contains the let-23 promoter, the entire gene,
and ;2 kb of 39 untranslated region (1). A 5.9-kb BamHI-SalI fragment from
pk7-13.8 was subcloned into pBluescript KS(1) (Stratagene, La Jolla, Calif.),
generating the clone pk7-6.1. Site-directed mutagenesis was carried out in pk7-
6.1 by the method of Deng and Nickoloff (14), which permits direct mutagenesis
of double-stranded circular DNA (Clontech Laboratories Inc., Palo Alto, Calif.).
Two mutagenic primers were synthesized: SKNot (59-ACCGCGGTGGCTA
GCGCTCTAGAAC-39), which changes the NotI restriction site in pBluescript to
an NheI site, and SA62 (59-GAGAGTGTGAAAAATACAGAAGTTCCAG
CTG-39), which introduces the let-23(sa62) mutation at position 5673 of let-23.
The mutated BamHI-SalI fragment was placed back into pk7-13.8, generating
pk7s62, which is different from pk7-13.8 only in that it carries the G-to-A
mutation at the same position in which it was detected in let-23(sa62) animals.
We constructed transgenic C. elegans by high-copy-number germ line trans-
formation (47). A mix of 20 ng of pk7s62 per ml, 10 ng of pMH86 (a plasmid
which rescues the Dpy-20 phenotype) per ml, and 170 ng of pBluescript carrier
DNA per ml was injected into let-23(mn23) unc-4(e120)/mnC1; dpy-20(e1282)
worms, and non-Dpy animals were picked. Some of these non-Dpy F1 transgenic
animals produced non-Dpy transgenic F2 progeny; these stable lines were ana-
lyzed to give the data in Table 2. mn23 is a null allele of let-23 (2, 3, 23).
Construction of C305Y and C313Y mutations in HER14. The C305Y and
C313Y mutants were constructed by using an Altered Sites in vitro mutagenesis
system from Promega. The mutant clones were excised from the pAlter vector
with KpnI and XbaI restriction digestion and inserted into the pRK5 vector by
blunt-end cloning into the blunt-ended XbaI site of the vector. The transcription
in these cells is driven by the cytomegalovirus promoter.
Alternatively, these two mutants as well as the wild-type and K721A clones
were cloned into the pLXSHD retroviral vector (48), using the XhoI site in the
vector polylinker.
NIH 3T3 2.2 cells, which lack endogenous EGFR (45), were transfected with
C305Y or C313Y clones together with a neomycin-resistant plasmid by the
calcium phosphate precipitation method (74). Two days after transfection, the
cells were split, seeded at a density of 100,000 cells per 10-cm-diameter dish, and
put under neomycin resistance selection by addition of 0.8 mg of Geneticin G418
(GIBCO) per ml to the medium. Resistant clones were picked after 3 weeks and
screened for EGFR by Western blotting (immunoblotting) with antibody RK-2
(41).
Alternatively, BOSC cells were transfected with the retroviral vector and viral
supernatants were used to infect NIH 3T3 cells as described previously (48).
Resistance to histidinol was selected by addition of 0.8 mg of histidinol (Sigma)
per ml. Resistant clones were picked and screened as described above.
Scoring vulval differentiation. Twenty young adult hermaphrodites were
placed on a plate, allowed to lay eggs for 2 h, and then removed from the plate.
All larvae on a plate were examined by Nomarski optics when they were at the
late L3 stage or early L4 stage. Vulval differentiation was scored as described
elsewhere (3). The values reported are the averages of three independent ex-
periments.
Cell ablation experiments and VPC fate assignment. Cell ablations were
performed as described previously (5, 68), using 3.5 mM sodium azide in the
mounting agar. We ablated all cells in the gonad primordium of let-23(sa62)
unc-4(e120)/mnC1 or let-23(sa62) unc-4(e120)/let-23(sa62) unc-4(e120) larvae
before the first division of the somatic gonad precursors Z1 and Z4. Ablations
were confirmed at or before the L2 lethargus. Animals were maintained at 208C
during the ablation procedure and all of development. VPC fates were assigned
as described elsewhere (34, 64, 66).
Scoring brood size. We picked let-23(sa62) unc-4(e120) animals or unc-4
control animals at the L4 stage, placing a single animal on each plate, and
observed them approximately every 12 h, counting the number of eggs or larvae
produced. (Some animals, at the end of their reproductive life, apparently be-
came egg laying defective, as larvae appeared while no eggs were observed. This
typically occurred in the last two to four 12-h intervals.) At each time point, we
transferred the parents to new plates and incubated the eggs left on the plates to
score larval viability or counted and removed the eggs, leaving the parent on the
plate. The brood was judged complete when no eggs or larvae were produced for
three consecutive 12-h intervals.
Mating test. We picked animals for the mating test at the L4 stage. Males of
genotype let-23(sa62)/let-23(sa62) unc-4(e120); him-5(e1490)/1 were placed sin-
gly on plates with four unc-52(e444) hermaphrodites each. After the animals
matured and produced progeny, we counted the non-Unc progeny that arose
from mating. The control cross used males of genotype unc-4/1; him-5/1.
Immunoprecipitation. Dishes of confluent cells were treated with 100 ng of
EGF per ml for 5 min and then washed three times with phosphate-buffered
saline, drained well, and scraped into 0.5 ml of lysis buffer (27). After 5 min of
incubation on ice, the lysate was centrifuged for 5 min in an Eppendorf centri-
fuge at 48C, and the supernatant was either used immediately or frozen at2708C.
EGFR was immunoprecipitated with antibody RK-2, a rabbit antiserum directed
against a synthetic peptide from the cytoplasmic domain, or with 108, a mono-
clonal antibody specific for human EGFR (7). Lysates were incubated with
protein A-Sepharose-antibody complex for 90 min at 48C and then washed three
times with lysis buffer.
Autophosphorylation. Immunoprecipitates were incubated on ice in lysis
buffer containing 5 mMMnCl2, 200 mM sodium orthovanadate, 15 mMunlabeled
ATP, and 1 mCi of [g-32P]ATP for 15 min. The reaction was stopped by addition
of sample buffer. The proteins were separated by electrophoresis on a sodium
dodecyl sulfate (SDS)–8% polyacrylamide gel.
125I-EGF binding experiments and Scatchard analysis. For all 125I-EGF bind-
ing assays, cells were plated at a density of 100,000 cells per well in 24-well dishes
coated with 10 mg of human plasma fibronectin (Meloy Laboratory) and grown
for 48 h to confluency in Dulbecco modified Eagle medium containing 10% calf
serum. Human recombinant EGF (Intergen) was iodinated by using the chlora-
mine T method to a specific activity of 1.5 3 108 cpm/mg.
Binding experiments and Scatchard analysis were performed as described
previously (27).
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RESULTS
sa62 confers a semidominant Muv phenotype. A strain car-
rying the sa62 mutation was isolated in the laboratory of J. H.
Thomas. We isolated sa62 from a complex genetic background
and examined vulval differentiation. In wild-type animals, 3.0
VPCs differentiate to vulval fates. The Muv phenotype was
observed in sa62 animals when more than three VPCs adopted
vulval fates, giving rise to ectopic pseudovulvae (Fig. 2B). In
animals homozygous for sa62, 3 to 5.5 (4.2 on average) VPCs
adopted vulval fates at 208C; 89% of homozygotes displayed
excess vulval differentiation (Table 1). In animals heterozygous
for sa62, three to four VPCs adopted vulval fates at 208C;
approximately 6% of heterozygotes displayed excess vulval dif-
ferentiation. The effect of the sa62 mutation is exerted zygot-
ically; maternal genotype did not affect the phenotype of the
progeny.
sa62 is caused by a point mutation in the extracellular
domain of let-23. We mapped sa62 genetically to within 0.1
map unit of let-23, a region corresponding to approximately
100 kb on the physical map. As other tyrosine kinases are
present in this interval, we performed a cis-trans test to dem-
onstrate that sa62 is an allele of let-23 (see Materials and
Methods).
We then sequenced the coding region of let-23 in sa62 ani-
mals and found a single point mutation (G to A) in cysteine-
rich domain I, close to the major ligand-binding domain (Fig.
1B). The mutation converts cysteine 359 to tyrosine. We re-
constructed the C359Y by site-directed mutagenesis. This re-
constructed mutant allele, when expressed as a transgene in
let-23(lethal) animals, was able to rescue the lethal phenotype.
Transgenic animals bearing this construct displayed excess vul-
val differentiation (Table 2; Fig. 2D). While we have not rig-
orously ruled out the possibility that an additional mutation in
noncoding sequence leads to overexpression of sa62 gene
product, extra copies of wild-type let-23 do not cause excess
vulval differentiation in transgenic animals (Table 2; Fig. 2C).
Therefore, the change at codon 359 is necessary and likely
sufficient to cause the semidominant Muv phenotype of sa62.
sa62 activity induces both vulval fates in a ligand-indepen-
dent, dose-dependent manner. In wild-type animals, a signal
from the anchor cell of the gonad is required to induce vulval
differentiation. When a laser microbeam is used to ablate the
gonad primordium of wild-type animals, no VPCs differentiate
to vulval fates (37, 68). When we ablated the gonad primor-
dium in sa62 animals, both sa62/1 heterozygotes and sa62
homozygotes displayed vulval differentiation (Table 3). Twen-
ty-two of 67 heterozygotes and all 14 homozygotes tested dis-
played vulval differentiation after gonad ablation. This result
demonstrates that let-23(sa62) can act in a ligand-independent
manner.
We observed a correlation between the copy number of
sa62, the number of VPCs induced to vulval fates, and the
types of vulval fates observed in gonad-ablated animals (Table
3; Fig. 3). In sa62 homozygotes, 58 of 78 VPCs adopted vulval
fates. Five of these 58 adopted the 18 fate, while 12 adopted a
fate that has properties of both 18 and 28 fates, designated
intermediate (34). In sa62 heterozygotes, only 38 of 368 VPCs
adopted vulval fates, and the 38 VPCs induced to vulval fates
adopted either the 28 fate or a fate having properties of both 38
and 28 fates (half-vulval). Strikingly, in these animals no VPCs
adopted the 18 or intermediate fate. This result indicates that
FIG. 2. Muv phenotype of sa62. Shown are Nomarski photomicrographs of
L4 hermaphrodites (A and B) and adult hermaphrodites (C and D). (A) Wild
type; (B) sa62; (C) let-23(sy17 null) with wild-type transgene; (D) let-23(sy17 null)
with sa62 transgene. Arrows, vulvae; arrowheads, pseudovulvae. Scale bars 5 20
mm.





No. of VPCs adopting indicated fate
38b Half-vulval 28 Intermediate 18
1/1 Many All 0 0 0 0
sa62/1 67 330 13 25 0 0
sa62/sa62 14 20 6 35 12 5
a sa62 is linked to unc-4(e120) as a marker; heterozygotes are balanced in trans
to mnC1.
b P3.p fused with the epidermal syncytium hyp7 without dividing in 34 het-
erozygotes and 6 homozygotes. This occurs in approximately 50% of intact
wild-type animals (33a, 64).
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receptor activity influences VPC fate specification in a dose-
dependent manner. The observation that a twofold difference
in sa62 copy number causes a large difference in the fraction of
VPCs that adopt vulval fates suggests that a threshold level of
receptor activity may be required for a VPC to adopt a vulval
fate.
Phenotypes affected by other let-23 mutations. let-23 acts at
multiple points in development. Reduction-of-function muta-
tions in let-23 cause four defects in addition to the vulval
defect: deformed male spicules (structures necessary for mat-
ing), infertility, larval lethality, and misspecification of the P11
and P12 neurectoblast fates. Since sa62 causes a vulval defect
that is the opposite of the let-23 reduction-of-function defect,
we investigated its effect on other let-23 functions.
We tested mating efficiency and examined male spicule
structure in sa62 homozygotes. sa62 males were able to sire
non-Unc cross progeny when mated with unc-52 hermaphro-
dites but at reduced frequency (6 of 22 sa62males were able to
sire cross progeny, while 17 of 20 control males were able to do
so). Hyperactivating the pathway by overexpressing LIN-3 in
transgenic animals gives rise to deformed spicules due to mis-
specification of cell fates (9). Inspection of sa62 male mating
structures revealed a defect in the bursa of the male tail but not
the spicule defect expected for the gain-of-function lineage
alteration. The bursa of the sa62 male tail appeared con-
stricted, and some of the rays were abnormally short or curved
(Fig. 4). This novel defect may identify another role for let-23
in development or may reflect aberrant activity of the mutant
receptor.
The average brood size of unmated sa62 hermaphrodites
was 173 at 208C, with a range of 45 to 276 (n 5 24). Control
animals assayed in parallel had an average brood size of 283,
with a range of 204 to 360 (n5 15). sa62 e120 animals laid eggs
at a slower rate (average peak rate of 24 eggs per 12 h) than
e120 controls (average peak rate of 73 eggs per 12 h) but
produced eggs over a slightly longer period. sa62 homozygotes
are scrawny and slow growing; the low brood size that we
observed in comparison with that of wild-type control strains
could indicate a partial defect in fertility or could merely re-
flect the sickliness of sa62 homozygotes. As described above,
transgenic sa62 rescued the lethality of let-23 null alleles. It
also rescued the sterile phenotype of let-23 null alleles: 28 of 30
transgenic animals were fertile.
No significant embryonic or larval lethality was observed in
sa62 strains. P11/P12 fate specification was normal in 79 sa62
animals examined (31a).
FIG. 3. Representative vulval lineages observed after gonad ablation. Lin-
eages were determined and classified as previously described (34). 38 lineages are
indicated as S S or S ss. In some animals, P3.p does not divide and is indicated
as S. Hybrid fates include S LL and ss LO. 28 fates include LLTN, LLLN, LLON,
LDTT, DDTT, and LLLN. Dotted boxes indicate intermediate fates; the solid
box indicates a 18 fate.
FIG. 4. Morphologies of mating structures in sa62 and wild-type males. (A) Wild type, ventral view; (B) sa62, ventral view; (C) wild type, lateral view; (D) sa62,
lateral view. Scale bars 5 20 mm.
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Genetic epistasis tests. The Muv phenotype of sa62 permits
genetic epistasis tests with genes in the signal transduction
pathway that have Vul mutant phenotypes. By analogy with the
activities of their homologs in other systems, the LIN-3 growth
factor is expected to act before LET-23, and the SEM-5 adap-
tor and LET-60 RAS to act after LET-23 in the signal trans-
duction pathway.
We constructed double mutant strains and compared their
vulval differentiation with that of single mutants (Table 4).
sa62 did not rescue the lethal phenotype of severe lin-3 alleles.
Therefore, we analyzed the strongest viable reduction of func-
tion lin-3 genotype. This genotype confers almost complete
lack of vulval differentiation. Animals homozygous both for
sa62 and severe lin-3 showed the Muv phenotype of sa62. Thus,
sa62 is epistatic to the lin-3 vulval defect, supporting the hy-
pothesis that LET-23 acts after LIN-3 in vulval differentiation.
Animals with either a sem-5 mutation or a dominant nega-
tive let-60 mutation display little or no vulval differentiation (6,
10, 19). Animals doubly mutant for sa62 and either sem-5 or
let-60(dn) also displayed very little vulval differentiation. Thus,
sem-5 and let-60 vulvaless mutations are epistatic to sa62, con-
sistent with activity after LET-23 in vulval differentiation.
lin-2, lin-7, and lin-10 mutations cause reduced vulval differ-
entiation (17, 18, 31, 36, 65, 67). The functions of their gene
products are not known; lin-10 encodes a novel protein (36).
Therefore, it is of interest to constrain their point of action
with respect to the signal transduction pathway. We found that
animals doubly mutant for sa62 and lin-2, lin-7, or lin-10 had
excess vulval differentiation, while lin-2, lin-7, or lin-10 alone
caused incomplete vulval differentiation. Thus, sa62 is epistatic
to these mutations, consistent with let-2, let-7, and let-10 acting
to help let-23 function effectively.
Activity of an analogous mutation in human EGFR. To
analyze further the activity of the gain-of-function mutation,
we constructed the analogous mutation in the human EGFR
(70) by in vitro mutagenesis, converting cysteine 305 to ty-
rosine. We also constructed a loss-of-function mutation anal-
ogous to let-23(sy10) by converting cysteine 313 to tyrosine
(Fig. 1B). We transfected NIH 3T3 cells that lack endogenous
EGFR, isolated stable cell lines containing each mutation, and
compared them in parallel experiments with well-characterized
cell lines carrying either wild-type HER14 or the kinase-inac-
tive mutant K721A (27). Confluent cells were incubated for 5
min with EGF and then lysed. The receptor was immunopre-
cipitated from the cell lysates with antibody RK-2, raised
against a synthetic peptide from the cytoplasmic domain (41).
To assay tyrosine phosphorylation, immunoprecipitated pro-
teins were analyzed by Western blotting with an antiphospho-
tyrosine antibody (33). The C305Y mutant receptor showed
EGF-dependent tyrosine phosphorylation, as did wild-type re-
ceptor (Fig. 5). However, neither the C313Y mutant receptor
nor the loss-of-function mutant K721A showed tyrosine phos-
phorylation, consistent with loss of function caused by the
C313Y mutation. Since equal amounts of protein were loaded
in all lanes, the low level of C313Y in the lower panel of Fig.
5 may be due to instability of the mutant gene product.
To exclude the unlikely possibility that the extracellular cys-
teine mutation C313Y might inactivate the intracellular kinase
domain, we performed an in vitro kinase assay. Both C305Y
and C313Y showed kinase activity in vitro, confirming that the
mutations do not exert their effects directly on receptor kinase
activity (Fig. 6).
To test whether the ligand-binding site was altered in the
mutant receptors, we performed immunoprecipitation with
FIG. 5. EGF-dependent Tyr phosphorylation of EGFR and mutant recep-
tors. Cells expressing either wild-type or mutant receptors were exposed to 100
ng of EGF per ml for 5 min and then subjected to cell solubilization, immuno-
precipitation (IP) with anti-EGFR antibody RK-2, separation by SDS-polyacryl-
amide gel electrophoresis, blotting, and analysis with an antiphosphotyrosine
(P-Tyr) antibody (top). The nitrocellulose filter was stripped and reblotted with
anti-EGFR antibody RK-2 (bottom).
FIG. 6. In vitro kinase assay of EGFR and mutant receptors. EGFR and
mutant receptors were immunoprecipitated with antibody RK-2. The immuno-
precipitates were phosphorylated with [g-32P]ATP and separated by SDS-poly-
acrylamide gel electrophoresis.













1 1 3.0 Many 4.2d 58
2 lin-3(weak) 0.8 22 4.4 21
3 lin-3(strong) 0.09 20 4.4 20
4 sem-5 0.5 20 0.4 21
5 let-60(dn)e 0f 10 0.8 22
6 lin-2 0.5 20 3.5 23
7 lin-7 1.0 20 4.3 22
8 lin-10 0.5 17 3.9 18
a Genotypes used in experiments 1 to 8 were as follows: 1, N2; 2, lin-3(n378)
unc-22(e66); 3, lin-3(n378)unc-22(e66)/unc-24(e138) lin-3(n1059) dpy-20(e1282);
4, sem-5(n2019); 5, let-60(sy100) dpy-20(e1282); 6, lin-2(e1309); 7, lin-7(e1413); 8,
unc-13(e51) lin-10(e1439).
b Average number of VPCs per animal that differentiated to vulval fates in vul;
let-23(1) animals. Data from reference 32.
c Average number of VPCs per animal that differentiated to vulval fates in vul;
sa62 animals. vul genotypes are the same as in footnote a. sa62 is linked to
unc-4(e120) in experiments 1 to 5.
d From Table 1.
e dn, a dominant negative allele.
f From reference 19.
534 KATZ ET AL. MOL. CELL. BIOL.
monoclonal antibody 108, raised against the major ligand-bind-
ing domain of EGFR (7). The antibody immunoprecipitated
C305Y but not C313Y (data not shown). This result indicates
that the ligand-binding site is not significantly altered in the
C305Y receptor but is altered in the C313Y receptor. The loss
of antibody binding suggests a conformational change affecting
the ligand-binding domain of the C313Y mutant receptor.
Assays of 125I-EGF binding to EGFR on living cells revealed
two distinct affinity states (38, 57). We performed Scatchard
plot analysis of 125I-EGF binding to cells expressing wild-type
receptor (275,000 receptors per cell) or C305Y mutant recep-
tor (50,000 receptors per cell). Binding curves at room tem-
perature are consistent with the existence of two classes of
binding sites in both cell lines. In the case of HER14, 2 to 3%
of the sites were in the high-affinity state (Kd 5 0.3 3 10
210 to
0.7 3 10210 M), and 97 to 98% were in the low-affinity state
(Kd 5 53 10
29 to 63 1029 M). In the case of C305Y, 3 to 4%
of the sites were in the high-affinity state with a slightly higher
Kd (0.15 3 10
29 to 0.2 3 1029 M), and 96 to 97% were in the
low-affinity state (Kd 5 4 3 10
29 to 5 3 1029 M). Cell lines
expressing the wild-type and mutant receptors, made by infec-
tion with a retroviral vector, gave similar Kd values. Infected
cell lines carrying wild-type, C305Y, or K721A receptor all
expressed similar numbers of receptors (approximately 300,000
per cell). Thus, the C305Y mutation does not alter the steady-
state number of receptors at the cell surface. The amount of
C313Y receptor per cell could not be estimated, since the
mutant receptor does not show any EGF binding.
DISCUSSION
We have shown that a single amino acid substitution in a
cysteine-rich extracellular domain of the LET-23 RTK causes
a gain-of-function phenotype. This is the first example in the
EGFR subfamily of activation caused by a single extracellular
amino acid substitution. In contrast, sy10, another point mu-
tation nine residues away in the same domain, which also
substitutes tyrosine for cysteine, reduces LET-23 function.
While sy10 is pleiotropic, sa62 visibly affects only one of several
developmental functions previously shown to depend on LET-
23. Genetic epistasis and cell ablation experiments suggest that
the sa62 phenotype may arise from ligand-independent activity
of the mutant gene product or from hypersensitivity to very low
levels of ligand. The copy number of sa62 influenced the vulval
fates produced, suggesting that levels of receptor activity affect
the choice of VPC fate.
Activation of RTKs by mutations in the extracellular do-
main.RTKs are grouped into classes based on molecular struc-
ture. Receptors of the EGFR class include EGFR, HER2/neu,
HER3/c-erbB-3, and HER4/p180erb4 of vertebrates, DER of
Drosophila melanogaster, and LET-23 of C. elegans (1, 49, 51,
71). These receptors consist of an extracellular domain, a sin-
gle transmembrane domain, and an intracellular domain (Fig.
1A). The extracellular domain contains four subdomains: two
that are thought to contribute most to ligand binding, alter-
nating with two cysteine-rich domains (56, 71).
Ligand binding appears to promote receptor dimerization
(reviewed in reference 22). Receptor dimerization leads to
intermolecular cross-phosphorylation of receptor, which re-
sults in signal transduction (22, 55, 56, 59, 71).
Changes in the structure of the extracellular domain can
activate RTKs. The leukemogenic insertionally activated ver-
sion of c-erbB deletes the extracellular binding domain (42); an
N-terminal truncation of human EGFR allows constitutive
self-renewal of erythroblasts (35). In-frame deletion of 7 to 12
extracellular residues activates Neu/c-erbB-2 (58). Insertion of
a cysteine residue in the extracellular juxtamembrane region of
EGFR increases affinity for ligand and kinase activity of the
receptor (59).
Point mutations in the exoplasmic domain of RTKs of other
subclasses can cause ligand-independent activation of RTKs.
Three torso gain-of-function alleles are caused by different
point mutations in the extracellular domain (60). Both the
feline and human c-fms proto-oncogenes are activated by a
point mutation at identical positions in the extracellular do-
main (53, 75). The neu oncogene contains a Val-to-Glu change
in the transmembrane domain. This change is postulated to
enhance oligomerization, leading to increased activity (62, 73).
An Arg-to-Cys change in the exoplasmic domain of the eryth-
ropoietin receptor causes factor-independent growth and ac-
cumulation in the endoplasmic reticulum and prevents the
rapid degradation characteristic of the wild-type receptor. The
new cysteine makes sulfide linkages postulated to mimic the
dimerization of the ligand-bound receptor (78).
The Cys-to-Tyr change in sa62 lies in cysteine-rich region II
of the extracellular domain. The cysteine-rich subdomains are
conserved, flank the major ligand-binding domain, and are in a
position to interact with adjacent receptors (56, 71). Thus, this
region of the extracellular domain may be involved in confor-
mational change upon ligand binding. The fact that the nearby
sy10 Cys-to-Tyr mutation causes the phenotype opposite that
of sa62 suggests that cysteines in this domain are important for
function but not all are equivalent in function.
The hypothesis that the sa62 mutation activates the RTK by
promoting ligand-independent dimerization and activation is
not supported by in vitro analysis of the analogous mutation in
human EGFR. This may reflect a unique interaction between
LET-23 and factors specific to vulval differentiation, or vulval
differentiation may be more sensitive to receptor activity than
other inductive events mediated by the same pathway.
Role of LET-23 in C. elegans vulval pattern formation. Re-
cent work has demonstrated that the EGF-like domain of
LIN-3, the vulval inductive signal, can influence vulval cell fate
in a dose-dependent manner (34). Here we demonstrate that
the sa62 mutation can act in a similar manner. Specifically, in
gonad-ablated animals, we observed a correlation between the
number of copies of the sa62 mutation, the extent of vulval
differentiation, and the presence or absence of the 18 fate. The
dependence of VPC fate on sa62 copy number is consistent
with a model in which graded levels of inductive signal induce
different vulval fates by stimulating distinct levels of LET-23
activity in VPCs receiving different levels of inductive signal.
Given the importance of these quantitative differences, we
propose that modulation of receptor activity in different VPCs
could be important in the specification of VPC fate.
It will be of interest to learn how quantitative differences in
signal or receptor activity give rise to qualitatively different
responses. One possibility is that quantitative information is
transduced via the Ras pathway. Investigations using cultured
mammalian cells have shown that quantitative differences in
EGFR activity are transduced via mitogen-activated protein
kinase and may affect the duration of phosphorylation of
downstream effectors (15, 69). Alternatively, different levels of
signal or receptor activity may stimulate distinct signal trans-
duction pathways. Investigations of other mammalian cell
types, as well as genetic studies of C. elegans, offer precedent
for this model (13, 32). These models can be tested by molec-
ular genetic investigation of the activities of downstream ef-
fectors in the vulval induction pathway and by genetic analysis
of interacting genes.
LIN-12, a transmembrane protein structurally similar to the
Drosophila Notch protein, appears to function downstream of
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LET-23 in a lateral signaling pathway that normally passes
between vulval precursor cells and is thought to be required for
specification of the 28 fate (reviewed in reference 63). Our
observation of 28 fates in gonad-ablated sa62 heterozygotes
suggests that intermediate levels of LET-23 activity can pro-
mote the 28 fate. While our data do not rule out a LIN-12-
independent mode of 28 fate specification, the LIN-12 signal-
ing pathway might be activated in response to intermediate
LET-23 activation.
Role of LET-23 in C. elegans signal transduction. We have
used let-23(sa62) to confirm the order of action of LET-23 in
the signal transduction pathway for vulval differentiation.
Taken together with previous observations that LET-23 is nec-
essary for vulval differentiation in response to overexpressed
LIN-3 (24), our epistasis and cell ablation experiments indicate
that LET-23 acts after LIN-3. By contrast, SEM-5 is necessary
for vulval differentiation stimulated by the sa62 gene product,
consistent with SEM-5 acting to transduce signal from LET-23
to LET-60. These results support the likelihood of interactions
proposed on the basis of the biochemical activity of mamma-
lian homologs. In particular, since human GRB2 can replace
SEM-5 functions in transgenic nematodes (61), we expect that
SEM-5 associates with activated LET-23 via its SH2 domain, as
its homolog GRB2 does with activated EGFR (46).
Three other genes, lin-2, lin-7, and lin-10, are only partly
required for vulval differentiation (17, 18, 31, 36, 65, 67). This
partial requirement is consistent with their helping the efficacy
of signaling, or acting in one of two parallel signal transduction
pathways. sa62 bypasses the requirement for lin-2, lin-7, and
lin-10. If these are indeed null alleles, our results suggest that
lin-2, lin-7, and lin-10 help in receptor synthesis or activation,
not as components of a second pathway.
Although we observed a novel defect in the male tail, we did
not observe the predicted defect in the male spicules, nor did
we find abnormalities in several other nonvulval phenotypes
that are affected by let-23 loss-of-function mutations or path-
way hyperactivity. Moreover, sa62 does not suppress the lethal
phenotype caused by a loss of function mutation of lin-3. These
differences suggest that the VPCs may be more sensitive than
other cells to increases in pathway activity. In support of this
possibility, the reduction-of-function mutation sy10 displays
more activity in vivo than the analogous mutation C313Y dis-
plays in vitro. Similarly, sa62 displays elevated activity in the
VPCs, while the analogous mutation C305Y has no significant
effect on the growth of 3T3 cells or on receptor activity in vitro.
Alternatively, interacting factors unique to the VPCs might
mediate the vulval differentiation phenotype of sa62. For ex-
ample, sa62 might cause a conformational change in the re-
ceptor that affects an interacting protein expressed only in the
VPCs. In either case, these observations support the possibility
that vulval differentiation provides a sensitive assay for subtle
variations in pathway activity. Analysis of vulval development
in C. elegans holds promise to elucidate novel aspects of re-
ceptor tyrosine kinase regulation and signal transduction.
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